Agios Pharmaceuticals (AGIO)

• Market cap: $1.61B
• 1 day: -0.43%
• 5 days: 2.07%
• 1 month: -2.58%
• 3 months: -36.76%
• 6 months: -22.02%
• Year to date: 1.51%
• 1 year: -15.91%
• 5 years: -50.64%
• 10 years: -26.93%
• Sector: Healthcare
• Industry: Biotechnology

About: Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Employees: 488